When to use bispecifics for AML
Description: As alternatives to chemotherapy are created, the prospect of having treatments with a lower toxicity becomes more tangible. In this video, Prof. John DiPersio, MD, PhD from Washington University School of Medicine, Washington, WA provides an insight into how to improve the chances of treating leukemia using bispecifics. Prof. DiPersio discusses when to use bispecifics, and the benefits it will have for patients who have recently undergone transplant or have a positive minimal residual disease status. This video was recorded at the International Conference on Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Haematology (ESH).
Shared By : VJHemOnc
Posted on : 11/24/17
Added : 1 year ago